Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Artelo Biosciences Inc ARTL

Healthcare
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid agonist for the G protein-coupled receptor... see more

Recent & Breaking News (NDAQ:ARTL)

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

GlobeNewswire April 23, 2024

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

GlobeNewswire April 22, 2024

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

GlobeNewswire March 25, 2024

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

GlobeNewswire March 12, 2024

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

Accesswire February 15, 2024

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

GlobeNewswire January 23, 2024

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

GlobeNewswire January 8, 2024

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

GlobeNewswire December 5, 2023

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

GlobeNewswire November 30, 2023

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 13, 2023

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

GlobeNewswire November 9, 2023

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

GlobeNewswire November 2, 2023

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

GlobeNewswire October 4, 2023

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

GlobeNewswire September 13, 2023

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

GlobeNewswire September 7, 2023

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

GlobeNewswire September 6, 2023

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

GlobeNewswire September 5, 2023

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 10, 2023

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

GlobeNewswire July 19, 2023

Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11

GlobeNewswire July 10, 2023